1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Diazepam |
| brand | String | Valium (oral, IV/IM, rectal), Diastat (rectal gel for breakthrough seizures), Valtoco (nasal spray for breakthrough seizures), Libervant (buccal film) |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Benzodiazepines|Benzodiazepine (long-acting)]] • [[:Category:Anxiolytics|Anxiolytic]] • [[:Category:Anticonvulsants|Anticonvulsant]] • [[:Category:Skeletal muscle relaxants|Skeletal muscle relaxant]] • [[:Category:Schedule IV controlled substances|Schedule IV controlled substance]] |
| mechanism | String | |
| uses | String | '"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' |
| starting_dose | String | Anxiety: 2-10 mg PO 2-4 times daily. Alcohol withdrawal: 10-20 mg PO/IV every 4-6 hours, symptom-triggered. Status epilepticus: 5-10 mg IV. Breakthrough seizures: Diastat rectal 0.2-0.5 mg/kg or Valtoco intranasal 5-20 mg |
| preparations | String | Tablets 2, 5, 10 mg; oral solution 1, 5 mg/mL; injection 5 mg/mL; Diastat rectal gel 2.5, 5, 10, 20 mg; Valtoco nasal spray 5, 7.5, 10 mg/dose; Libervant buccal film |
| fda_max | String | 40 mg/day (oral, anxiety) |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral • IV • IM • rectal • intranasal • buccal |
| onset | String | 15-60 minutes (oral); 1-5 minutes (IV); 4-10 minutes (rectal or intranasal) |
| duration | String | 6-24 hours (parent); much longer when accounting for the long-lived active metabolites |
| halflife | String | Diazepam 20-50 hours; '''N-desmethyldiazepam (nordazepam) 30-200 hours''' is the major active metabolite and accumulates substantially with chronic dosing'"`UNIQ--ref-00000026-QINU`"' |
| bioavailability | String | ~93% (oral); ~90% (rectal)'"`UNIQ--ref-00000027-QINU`"' |
| pregnancy | String | Some signal for cleft palate with first-trimester exposure (debated); neonatal sedation and withdrawal with third-trimester exposure.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| legal | String | [[USLegal:Schedule IV|Schedule IV controlled substance]] in US. Carries the benzodiazepine class '''Boxed Warning''' for risk of fatal respiratory depression, coma, and death when combined with opioids'"`UNIQ--ref-00000028-QINU`"' |
